Yabao In-Licenses China Rights to Lilly Diabetes Drug Candidate

Yabao Pharma of China formed a partnership with Eli Lilly to co-develop an innovative Lilly treatment for type 2 diabetes. The drug, LY2608204, is a glucokinase activator (GKA) that has completed a US Phase I trial. Yabao will fund China development of LY2608204 and own rights to market the drug in China. Lilly retains buy-in options to the program. Financial details were not disclosed. More details..... Stock Symbols: (SHA: 600351) (NYSE: LLY) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.